All Stories

  1. Cross talk between the liver microbiome and epigenome in patients with metabolic dysfunction-associated steatotic liver disease
  2. From NAFLD to MASLD: Updated Naming and Diagnosis Criteria for Fatty Liver Disease
  3. Non‐alcoholic fatty liver disease mediates the effect of obesity on arterial hypertension
  4. SARS-CoV-2 targets the liver and manipulates glucose metabolism
  5. Editorial: NAFLD , chronic kidney disease, and pleiotropy—Why is PNPLA3 omnipresent?
  6. Advances in our understanding of the molecular heterogeneity of fatty liver disease: towards informed treatment decision making
  7. Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response
  8. COVID ‐19 and NAFLD : biological insights from multi‐omics data
  9. Personalized medicine in nonalcoholic fatty liver disease
  10. Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait
  11. Geographical similarity and differences in the burden and genetic predisposition of NAFLD
  12. Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease
  13. Single cell gene expression profiling of nasal ciliated cells reveals distinctive biological processes related to epigenetic mechanisms in patients with severe COVID-19
  14. The serum uric acid/creatinine ratio is associated with nonalcoholic fatty liver disease in the general population
  15. PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features
  16. MicroRNAs as messengers of liver diseases: has the message finally been decrypted?
  17. The influence of host genetics on liver microbiome composition in patients with NAFLD
  18. Computational Pipeline for Next-Generation Sequencing (NGS) Studies in Genetics of NASH
  19. Single cell gene expression profiling of nasal ciliated cells reveals distinctive biological processes related to epigenetic mechanisms in patients with severe COVID-19
  20. Genome‐wide association study of liver‐related enzymes suggests putative pleiotropic effects on diverse traits and diseases
  21. PNPLA3 and COVID‐19 outcomes: Thinking outside the box might explain the biology behind pleiotropic effects of rs738409 on the immune system
  22. Editorial: bariatric surgery to reduce the risk of liver cancer
  23. The lipidome in nonalcoholic fatty liver disease: actionable targets
  24. NAFLD and cardiometabolic risk factors: The liver fibrosis trajectory through the lens of biological interactions
  25. Liver mitochondrial DNA damage and genetic variability of Cytochrome b ‐ a key component of the respirasome ‐ drive the severity of fatty liver disease
  26. Epigenetics factors in nonalcoholic fatty liver disease
  27. ADH1B∗2 Is Associated With Reduced Severity of Nonalcoholic Fatty Liver Disease in Adults, Independent of Alcohol Consumption
  28. SARS‐CoV‐2 virus and liver expression of host receptors: Putative mechanisms of liver involvement in COVID‐19
  29. COVID-19 and ACE2 in the Liver and Gastrointestinal Tract: Putative Biological Explanations of Sexual Dimorphism
  30. Genetic pathways in nonalcoholic fatty liver disease: Insights from systems biology
  31. Liver tissue microbiota linked to nonalcoholic fatty liver disease
  32. Review article: shared disease mechanisms between non-alcoholic fatty liver disease and metabolic syndrome - translating knowledge from systems biology to the bedside
  33. Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease
  34. Editorial: surviving your genes-the role of PNPLA3 variation in end-stage liver disease
  35. A Rare Nonsense Mutation in the Glucokinase Regulator Gene Is Associated With a Rapidly Progressive Clinical Form of Nonalcoholic Steatohepatitis
  36. Metastasis-associated lung adenocarcinoma transcript 1 as a common molecular driver in the pathogenesis of nonalcoholic steatohepatitis and chronic immune-mediated liver damage
  37. Lack of evidence supporting a role of TMC4-rs641738 missense variant—MBOAT7- intergenic downstream variant—in the Susceptibility to Nonalcoholic Fatty Liver Disease
  38. The nonalcoholic steatohepatitis metabotype: Imbalance of circulating amino acids and transamination reactions reflect impaired mitochondrial function
  39. Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease
  40. Letter: Mendelian randomisation to investigate moderate alcohol consumption in nonalcoholic fatty liver disease; modest effects need large numbers-authors' reply
  41. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients
  42. How Safe Is Moderate Alcohol Consumption in Overweight and Obese Individuals?
  43. Serum aminotransferases in nonalcoholic fatty liver disease are a signature of liver metabolic perturbations at the amino acid and Krebs cycle level,